메뉴 건너뛰기




Volumn 62, Issue 25, 2013, Pages 521-524

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Author keywords

[No Author keywords available]

Indexed keywords

13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; VACCINE;

EID: 84879566035     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (176)

References (13)
  • 1
    • 33646858444 scopus 로고    scopus 로고
    • CDC. GRADE evidence tables-recommendations in MMWR. Atlanta, GA, CDC, Available at
    • CDC. GRADE evidence tables-recommendations in MMWR. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/vaccines/acip/recs/grade/table-refs.html.
    • (2013) US Department of Health and Human Services
  • 2
    • 82555164974 scopus 로고    scopus 로고
    • ACIP Evidence Based Recommendations Work Group. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC)
    • Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ; ACIP Evidence Based Recommendations Work Group. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171-6.
    • (2011) Vaccine , vol.29 , pp. 9171-9176
    • Ahmed, F.1    Temte, J.L.2    Campos-Outcalt, D.3    Schunemann, H.J.4
  • 3
    • 79954645991 scopus 로고    scopus 로고
    • Healthcare utilization and cost of pneumococcal disease in the United States
    • Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398-412.
    • (2011) Vaccine , vol.29 , pp. 3398-3412
    • Huang, S.S.1    Johnson, K.M.2    Ray, G.T.3
  • 4
    • 78650215295 scopus 로고    scopus 로고
    • Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • CDC, No. RR-11
    • CDC. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-11).
    • (2010) MMWR , vol.59
  • 5
    • 77956229614 scopus 로고    scopus 로고
    • Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization
    • Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010;24:2253-62.
    • (2010) AIDS , vol.24 , pp. 2253-2262
    • Cohen, A.L.1    Harrison, L.H.2    Farley, M.M.3
  • 6
    • 84868018443 scopus 로고    scopus 로고
    • Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • CDC
    • CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61:816-9.
    • (2012) MMWR , vol.61 , pp. 816-819
  • 7
    • 0141430931 scopus 로고    scopus 로고
    • A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
    • Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8.
    • (2003) N Engl J Med , vol.349 , pp. 1341-1348
    • Klugman, K.P.1    Madhi, S.A.2    Huebner, R.E.3    Kohberger, R.4    Mbelle, N.5    Pierce, N.6
  • 8
    • 77649329574 scopus 로고    scopus 로고
    • A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
    • French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812-22.
    • (2010) N Engl J Med , vol.362 , pp. 812-822
    • French, N.1    Gordon, S.B.2    Mwalukomo, T.3
  • 9
    • 40949107353 scopus 로고    scopus 로고
    • Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life
    • Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008;121:562-9.
    • (2008) Pediatrics , vol.121 , pp. 562-569
    • Adamkiewicz, T.V.1    Silk, B.J.2    Howgate, J.3
  • 11
    • 18644379800 scopus 로고    scopus 로고
    • Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children
    • Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005;24:410-6.
    • (2005) Pediatr Infect Dis J , vol.24 , pp. 410-416
    • Madhi, S.A.1    Kuwanda, L.2    Cutland, C.3    Holm, A.4    Kayhty, H.5    Klugman, K.P.6
  • 12
    • 0037743433 scopus 로고    scopus 로고
    • Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection
    • Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003;112(1 Pt 1):66-73.
    • (2003) Pediatrics , vol.112 , Issue.1 PART 1 , pp. 66-73
    • Nachman, S.1    Kim, S.2    King, J.3
  • 13
    • 33749426110 scopus 로고    scopus 로고
    • Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy
    • Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:920-9.
    • (2006) Pediatr Infect Dis J , vol.25 , pp. 920-929
    • Abzug, M.J.1    Pelton, S.I.2    Song, L.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.